Nidol (Nimesulide)

Nimesulide works by preferentially inhibiting the cyclooxygenase‑2 (COX‑2) enzyme, which reduces the production of prostaglandins that mediate pain, fever, and inflammation. This selective action aims to maintain anti‑inflammatory efficacy while limiting COX‑1‑related gastrointestinal side effects.

The exact dose of Nidol is determined by the prescribing clinician based on the patient’s condition, age, and overall health. Healthcare professionals follow local prescribing guidelines and adjust the regimen to achieve optimal pain control while minimizing risk.

Nidol is generally not recommended for use during pregnancy, especially in the third trimester, due to potential fetal risks. Limited data are available for breastfeeding mothers, and caution is advised; alternative therapies are usually preferred.

To request Nidol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with non‑selective NSAIDs, nimesulide offers a higher degree of COX‑2 selectivity, which may reduce the incidence of gastrointestinal irritation. However, it still carries risks of hepatic and renal effects, so clinicians weigh these factors against alternatives such as ibuprofen or diclofenac.

Nidol should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in their original packaging, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Nidol is taken orally, usually with a full glass of water. It can be taken with or without food, but patients who experience stomach upset may benefit from taking it with meals as advised by their healthcare provider.

The most serious adverse events include hepatotoxicity, severe skin reactions such as Stevens‑Johnson syndrome, gastrointestinal bleeding or ulceration, and acute renal impairment. Patients should be instructed to seek immediate medical attention if they notice signs of liver dysfunction, rash, or gastrointestinal bleeding.

Nidol should be avoided in individuals with known hypersensitivity to nimesulide or other NSAIDs, those with active peptic ulcer disease, severe hepatic or renal impairment, and patients in the third trimester of pregnancy. Clinicians should also assess cardiovascular risk before prescribing.